{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:20:07Z","timestamp":1789611607042,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Lockdown measures during the first wave of the COVID-19 pandemic in France led to serious public health concerns over people who use illicit drugs, especially in terms of mental health. We assessed changes in cannabis use during the first lockdown in France among daily cannabis users and associated correlates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>CANNAVID is a French, national, cross-sectional web-based survey, conducted from 17 April to 11 May 2020. Daily cannabis users aged\u2009\u2265\u200918\u00a0years and living in France were invited to participate through advertisements. Respondents completed an ad hoc questionnaire on a dedicated online platform. We analyzed changes in cannabis use during the first lockdown (<jats:italic>i.e.,<\/jats:italic>stopped, decreased, unchanged, or increased) and performed a multinomial logistic regression analysis to evaluate correlates of these changes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 4019 participants, 74.0% were men. Median age was 27\u00a0years (interquartile range: 22\u201337). With regard to cannabis use, 293 (7.3%) persons stopped, 1153 (28.7%) decreased, 1146 (28.5%) did not change, and 1427 (35.5%) increased their use during the lockdown. A multinomial logistic regression model revealed several sociodemographic, behavioral and health-related factors associated with changes in cannabis use. Compared with participants with an unchanged level of cannabis use during the lockdown, those who increased and those who stopped cannabis use were more likely to have increased tobacco and alcohol use and to have experienced depression and sleep disorders intensification. Those who stopped cannabis use were also more likely to have increased benzodiazepine use and to have experienced pain increase during lockdown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>France\u2019s first COVID-19-related lockdown had a differential impact on daily cannabis users\u2019 consumption patterns. Most study respondents reported changes to their cannabis consumption pattern. Those who reported a stable cannabis use were more likely to report fewer negative changes. Specific interventions are needed for this population, as well as research to assess the long-term impacts of these changes.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12954-022-00611-x","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T11:03:01Z","timestamp":1647342181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Changes in cannabis use and associated correlates during France\u2019s first COVID-19 lockdown in daily cannabis users: results from a large community-based online survey"],"prefix":"10.1186","volume":"19","author":[{"given":"Salim","family":"Mezaache","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Donadille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebla","family":"Le Brun Gadelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Appel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Spire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laelia","family":"Briand Madrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bastien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5069-4982","authenticated-orcid":false,"given":"Perrine","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"611_CR1","doi-asserted-by":"crossref","unstructured":"Davies NG, Kucharski AJ, Eggo RM, Gimma A, Edmunds WJ, Jombart T, et al. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. Lancet Public Health. 2020.","DOI":"10.1101\/2020.04.01.20049908"},{"key":"611_CR2","unstructured":"D\u00e9cret n\u00b0 2020-293 du 23 mars 2020 prescrivant les mesures g\u00e9n\u00e9rales n\u00e9cessaires pour faire face \u00e0 l\u2019\u00e9pid\u00e9mie de covid-19 dans le cadre de l\u2019\u00e9tat d\u2019urgence sanitaire. Mar 23, 2020."},{"key":"611_CR3","unstructured":"D\u00e9cret n\u00b0 2020-264 du 17 mars 2020 portant cr\u00e9ation d\u2019une contravention r\u00e9primant la violation des mesures destin\u00e9es \u00e0 pr\u00e9venir et limiter les cons\u00e9quences des menaces sanitaires graves sur la sant\u00e9 de la population. 2020-264 Mar 17, 2020."},{"issue":"3","key":"611_CR4","doi-asserted-by":"publisher","first-page":"e19630","DOI":"10.2196\/19630","volume":"6","author":"B Rolland","year":"2020","unstructured":"Rolland B, Haesebaert F, Zante E, Benyamina A, Haesebaert J, Franck N. Global changes and factors of increase in caloric\/salty food intake, screen use, and substance use during the early COVID-19 containment phase in the general population in France: survey study. JMIR Public Health Surveill. 2020;6(3):e19630.","journal-title":"JMIR Public Health Surveill"},{"key":"611_CR5","doi-asserted-by":"crossref","unstructured":"Pullano G, Valdano E, Scarpa N, Rubrichi S, Colizza V. Evaluating the impact of demographic, socioeconomic factors, and risk aversion on mobility during COVID-19 epidemic in France under lockdown: a population-based study. medRxiv. 2020;2020.05.29.20097097.","DOI":"10.1101\/2020.05.29.20097097"},{"key":"611_CR6","unstructured":"G\u00e9rome C, Gandilhon M. Evolution des usages et de l\u2019offre de drogues au temps du COVID-19\u202f: observations crois\u00e9es du dispositif TREND. Saint-Denis: Observatoire Fran\u00e7ais des Drogues et des Toxicomanies; 2020. p. 20. (Bulletin TREND-COVID19). Report No.: 2. https:\/\/www.ofdt.fr\/BDD\/publications\/docs\/Bulletin-TREND-COVID-2.pdf."},{"issue":"4","key":"611_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.therap.2020.06.006","volume":"75","author":"M Lapeyre-Mestre","year":"2020","unstructured":"Lapeyre-Mestre M, Boucher A, Daveluy A, Gibaja V, Jouanjus E, Mallaret M, et al. Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapies. 2020;75(4):343\u201354.","journal-title":"Therapies"},{"key":"611_CR8","doi-asserted-by":"publisher","first-page":"108580","DOI":"10.1016\/j.drugalcdep.2021.108580","volume":"221","author":"JJ Palamar","year":"2021","unstructured":"Palamar JJ, Le A, Carr TH, Cottler LB. Shifts in drug seizures in the United States during the COVID-19 pandemic. Drug Alcohol Depend. 2021;221:108580.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"611_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13011-021-00373-y","volume":"16","author":"J Manthey","year":"2021","unstructured":"Manthey J, Kilian C, Carr S, Bartak M, Bloomfield K, Braddick F, et al. Use of alcohol, tobacco, cannabis, and other substances during the first wave of the SARS-CoV-2 pandemic in Europe: a survey on 36,000 European substance users. Subst Abuse Treat Prev Policy. 2021;16(1):36.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"6","key":"611_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000510822","volume":"26","author":"N Vanderbruggen","year":"2020","unstructured":"Vanderbruggen N, Matthys F, Van Laere S, Zeeuws D, Santermans L, Van den Ameele S, et al. Self-reported alcohol, tobacco, and cannabis use during COVID-19 lockdown measures: results from a web-based survey. Eur Addict Res. 2020;26(6):309\u201315.","journal-title":"Eur Addict Res"},{"key":"611_CR11","doi-asserted-by":"publisher","first-page":"108488","DOI":"10.1016\/j.drugalcdep.2020.108488","volume":"219","author":"L Jacob","year":"2021","unstructured":"Jacob L, Smith L, Armstrong NC, Yakkundi A, Barnett Y, Butler L, et al. Alcohol use and mental health during COVID-19 lockdown: a cross-sectional study in a sample of UK adults. Drug Alcohol Depend. 2021;219:108488.","journal-title":"Drug Alcohol Depend"},{"key":"611_CR12","unstructured":"Spilka S, Richard J-B, Le N\u00e9zet O, Janssen E, Brissot A, Philippon A, et al. Les niveaux d\u2019usage des drogues illicites en France en 2017 [Internet]. Saint-Denis: Observatoire Fran\u00e7ais des Drogues et des Toxicomanies; 2018. p. 4. (Tendances). https:\/\/www.ofdt.fr\/BDD\/publications\/docs\/eftxssyb.pdf."},{"issue":"4","key":"611_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/09595230310001613976","volume":"22","author":"B Green","year":"2003","unstructured":"Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev. 2003;22(4):453\u201360.","journal-title":"Drug Alcohol Rev"},{"key":"611_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euroneuro.2020.02.003","volume":"33","author":"E Campeny","year":"2020","unstructured":"Campeny E, L\u00f3pez-Pelayo H, Nutt D, Blithikioti C, Oliveras C, Nu\u00f1o L, et al. The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harms. Eur Neuropsychopharmacol. 2020;33:1\u201335.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"25","key":"611_CR15","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.2174\/13816128113199990620","volume":"20","author":"L Karila","year":"2014","unstructured":"Karila L, Roux P, Rolland B, Benyamina A, Reynaud M, Aubin H-J, et al. Acute and long-term effects of cannabis use: a review. Curr Pharm Des. 2014;20(25):4112\u20138.","journal-title":"Curr Pharm Des"},{"issue":"5","key":"611_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1365-2125.2011.03970.x","volume":"72","author":"ME Lynch","year":"2011","unstructured":"Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735\u201344.","journal-title":"Br J Clin Pharmacol"},{"issue":"17","key":"611_CR17","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","volume":"82","author":"BS Koppel","year":"2014","unstructured":"Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556\u201363.","journal-title":"Neurology"},{"key":"611_CR18","first-page":"009464","volume":"11","author":"LA Smith","year":"2015","unstructured":"Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015;11:009464.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"611_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/02791072.2000.10400245","volume":"32","author":"AC Ogborne","year":"2000","unstructured":"Ogborne AC, Smart RG, Weber T, Birchmore-Timney C. Who is using cannabis as a medicine and why: an exploratory study. J Psychoactive Drugs. 2000;32(4):435\u201343.","journal-title":"J Psychoactive Drugs"},{"issue":"6","key":"611_CR20","doi-asserted-by":"publisher","first-page":"E755","DOI":"10.36076\/ppj.20.5.E755","volume":"20","author":"J Aviram","year":"2017","unstructured":"Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20(6):E755\u201396.","journal-title":"Pain Physician"},{"issue":"4","key":"611_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11920-017-0775-9","volume":"19","author":"KA Babson","year":"2017","unstructured":"Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep. 2017;19(4):23.","journal-title":"Curr Psychiatry Rep"},{"key":"611_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.socscimed.2019.06.005","volume":"233","author":"JD Kosiba","year":"2019","unstructured":"Kosiba JD, Maisto SA, Ditre JW. Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: systematic review and meta-analysis. Soc Sci Med. 2019;233:181\u201392.","journal-title":"Soc Sci Med"},{"issue":"2","key":"611_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/ptr.3375","volume":"25","author":"JA Farrimond","year":"2011","unstructured":"Farrimond JA, Mercier MS, Whalley BJ, Williams CM. Cannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation. Phytother Res. 2011;25(2):170\u201388.","journal-title":"Phytother Res"},{"key":"611_CR24","doi-asserted-by":"crossref","unstructured":"Donovan KA, Portman DG. Effect of COVID-19 pandemic on cannabis use in cancer patients. Am J Hosp Palliat Care. 2021;1049909121999784.","DOI":"10.1177\/1049909121999784"},{"key":"611_CR25","doi-asserted-by":"crossref","unstructured":"Vidot DC, Islam JY, Marlene Camacho-Rivera, Harrell MB, Rao DR, Chavez JV, et al. The COVID-19 cannabis health study: Results from an epidemiologic assessment of adults who use cannabis for medicinal reasons in the United States. J Addict Dis. 2021;39(1):26\u201336.","DOI":"10.1080\/10550887.2020.1811455"},{"key":"611_CR26","doi-asserted-by":"crossref","unstructured":"Cousijn J, Kuhns L, Larsen H, Kroon E. For better or for worse? A pre-post exploration of the impact of the COVID-19 lockdown on cannabis users. Addiction. 2021.","DOI":"10.1111\/add.15387"},{"issue":"16","key":"611_CR27","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","volume":"158","author":"K Bush","year":"1998","unstructured":"Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789\u201395.","journal-title":"Arch Intern Med"},{"key":"611_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2458-9-33","volume":"9","author":"G Rey","year":"2009","unstructured":"Rey G, Jougla E, Fouillet A, H\u00e9mon D. Ecological association between a deprivation index and mortality in France over the period 1997\u20132001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9:33.","journal-title":"BMC Public Health"},{"issue":"6","key":"611_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"611_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.601653\/full","author":"MW van Laar","year":"2020","unstructured":"van Laar MW, Oomen PE, van Miltenburg CJA, Vercoulen E, Freeman TP, Hall WD. Cannabis and COVID-19: reasons for concern. Front Psychiatry. 2020. https:\/\/doi.org\/10.3389\/fpsyt.2020.601653\/full.","journal-title":"Front Psychiatry"},{"issue":"2","key":"611_CR31","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/pubmed\/fdy090","volume":"41","author":"B Fischer","year":"2019","unstructured":"Fischer B, Russell C, Rehm J, Leece P. Assessing the public health impact of cannabis legalization in Canada: core outcome indicators towards an \u2018index\u2019 for monitoring and evaluation. J Public Health (Oxf). 2019;41(2):412\u201321.","journal-title":"J Public Health (Oxf)"},{"issue":"1","key":"611_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1037\/amp0000716","volume":"76","author":"KM Kniffin","year":"2021","unstructured":"Kniffin KM, Narayanan J, Anseel F, Antonakis J, Ashford SP, Bakker AB, et al. COVID-19 and the workplace: implications, issues, and insights for future research and action. Am Psychol. 2021;76(1):63\u201377.","journal-title":"Am Psychol"},{"issue":"1","key":"611_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/can.2016.0007","volume":"1","author":"M Sexton","year":"2016","unstructured":"Sexton M, Cuttler C, Finnell JS, Mischley LK. A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 2016;1(1):131\u20138.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"611_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ajad.12963","volume":"29","author":"SL Botsford","year":"2020","unstructured":"Botsford SL, Yang S, George TP. Cannabis and cannabinoids in mood and anxiety disorders: impact on illness onset and course, and assessment of therapeutic potential. Am J Addict. 2020;29(1):9\u201326.","journal-title":"Am J Addict"},{"issue":"1\u20133","key":"611_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.drugalcdep.2011.11.007","volume":"123","author":"DA Gorelick","year":"2012","unstructured":"Gorelick DA, Levin KH, Copersino ML, Heishman SJ, Liu F, Boggs DL, et al. Diagnostic criteria for cannabis withdrawal syndrome. Drug Alcohol Depend. 2012;123(1\u20133):141\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"611_CR36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jech-2020-215060","volume":"75","author":"CL Niedzwiedz","year":"2021","unstructured":"Niedzwiedz CL, Green MJ, Benzeval M, Campbell D, Craig P, Demou E, et al. Mental health and health behaviours before and during the initial phase of the COVID-19 lockdown: longitudinal analyses of the UK Household Longitudinal Study. J Epidemiol Community Health. 2021;75(3):224\u201331.","journal-title":"J Epidemiol Community Health"},{"issue":"10231","key":"611_CR37","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S0140-6736(20)30818-7","volume":"395","author":"P Webster","year":"2020","unstructured":"Webster P. Virtual health care in the era of COVID-19. The Lancet. 2020;395(10231):1180\u20131.","journal-title":"The Lancet"},{"issue":"8","key":"611_CR38","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S2215-0366(20)30260-1","volume":"7","author":"TR Soron","year":"2020","unstructured":"Soron TR, Shariful Islam SM, Ahmed HU, Ahmed SI. The hope and hype of telepsychiatry during the COVID-19 pandemic. Lancet Psychiatry. 2020;7(8):e50.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"611_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC Van Boekel","year":"2013","unstructured":"Van Boekel LC, Brouwers EPM, Van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. Drug Alcohol Depend. 2013;131(1):23\u201335.","journal-title":"Drug Alcohol Depend"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-022-00611-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T08:52:04Z","timestamp":1726822324000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-022-00611-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1186\/s12954-022-00611-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"assertion":[{"value":"8 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants received information before enrolment and provided oral consent. No signed consent was requested to ensure participants\u2019 anonymity (Yoshida et al., 2013). Moreover, no other personal data which could have led to the identification of the study participants (e.g., names, IP addresses) were collected. Ethical approval was granted by the French Inserm National Ethics Committee (IRB00003888; IORG0003254; FWA00005831) under the number N\u00b020-676.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}